Resources

How was this guide researched?

What was the research process?

Research was conducted across 14 structured prompts, each focused on a distinct evidence area. Taken together, they covered:

• systematic reviews and meta-analysis of CBD for pain and arthritis
• Mechanisms of action (how CBD interacts with the body's pain and inflammation systems)
• Institutional positions from rheumatology, integrative medicine, and regulatory bodies
• Safety profile: drug interactions, liver effects, adverse events in clinical trials
• Product quality: labeling accuracy, contamination, Certificate of Analysis standards
• Cost and access: price ranges, what insurance covers, how to evaluate products
• Legal landscape: federal status, state variation, the 2026 regulatory changes
• Patient behavior: what surveys show about who uses CBD, why, and what they report
• Comparison to other treatments: conventional osteoarthritis therapies and other supplements
• Content design: how health consumers evaluate evidence, what framing serves clarity

Over 250 sources were identified across all research prompts. Sources that passed inclusion criteria are cited in the pages where their findings appear.

What sources did we prioritize?

Sources were selected and prioritized in the following order:

1. Systematic reviews and meta-analyses — studies that pool and analyze all available evidence on a question. Highest priority because they are less susceptible to the chance findings of individual studies.
2. Randomized controlled trials (RCTs) — studies where participants are randomly assigned to CBD or placebo. The only study design that can establish whether CBD caused an observed effect in humans.
3. Clinical practice guidelines with publication dates noted — recommendations from professional bodies (ACR, EULAR, OARSI, CRA) based on their review of the evidence. Guideline dates matter: a 2019 guideline may not reflect 2023–2025 trial results.
4. Institutional position statements — positions from the Arthritis Foundation, NIH/NCCIH, WHO, and FDA on CBD safety and effectiveness.
5. Government regulatory documents — FDA warning letters, FTC enforcement actions, FDA surveillance data on CBD product labeling and contamination.
6. Large observational studies and surveys — used to describe what CBD users report and how many use CBD, with explicit acknowledgment that surveys cannot establish causation.

What did we exclude?

• Studies from predatory journals — publications that charge authors to publish without meaningful peer review, which cannot be relied on for quality control.
• Animal studies extrapolated to humans without replication — animal data was used only to explain mechanisms of action, with explicit tagging that the finding has not been confirmed in people. About 1 out of 20 treatments that work in animals are eventually approved for humans. ^{(Ineichen 2024)}
• Testimonials and uncontrolled case series — individual patient stories and collections of anecdotes cannot establish that CBD caused an observed change.
• Studies with undisclosed industry funding — research where the funding source is not disclosed cannot be evaluated for potential bias.
• Marketing materials presented as research — white papers, brand-commissioned studies, and other materials produced by companies with a financial interest in the outcome.

How did we rate evidence?

Evidence is rated using the GRADE framework — the same system used by Cochrane, the WHO, and most major clinical guideline bodies. GRADE assigns each finding one of four certainty levels: High, Moderate, Low, or Very Low.

For CBD and arthritis, most findings are rated Low or Very Low. The two main reasons are:

• Indirectness: Many CBD claims rest on animal or lab research that has not been confirmed in human trials.
• Imprecision: The total number of people studied in osteoarthritis-specific CBD trials is about 270 across three studies — small enough that results could shift substantially with new data.

Full explanation of GRADE ratings, what each level means, and how they were applied to CBD claims.

Why do we tag evidence by source type?

Every claim on this site carries a tag showing whether it comes from a human trial, a human survey, an animal study, or a lab study. This matters because CBD has an unusual evidence structure: most of the positive findings about CBD and inflammation come from animal and lab research. When researchers tested CBD for arthritis pain in controlled human trials, all three trials found no benefit over placebo.

Without source type tags, a finding from a rat model can look identical to a finding from a human trial. The tags make that distinction visible at a glance.

Why animal studies often do not predict what happens in people — and why this matters especially for CBD.

Known limitations of this guide

Author disclosure

Last reviewed: March 2026

Full drug interaction guide, medication checker, and pharmacist discussion checklist.

Full drug interaction guide, medication checker, and pharmacist discussion checklist.

Page last reviewed: March 2026 · Authored by Claude (Anthropic AI)